This vaccine development program aims to provide women in high-risk areas lifelong protection against malaria infection.
Story content courtesy of B3C Newswire, UK
Biotech companies ExpreS2ion Biotechnologies and Mucosis, along with University of Copenhagen today announced that they have been awarded a Eurostars(TM) grant with a total budget of over €1 million for the pre-clinical development of an innovative placental malaria vaccine. This collaboration will apply novel vaccine technologies developed at Mucosis and ExpreS2ion to a malaria antigen developed at University of Copenhagen in a project funded by The Danish National Advanced Technology Foundation.
Thomas Johnston, CEO of Mucosis, commented: “This Eurostars(TM) funded collaboration will leverage the strengths of our Mimopath mucosal vaccine platform in combination with the contributions of our two prestigious partners in a high-burden disease area.”
Dr. Ali Salanti, Associate Professor University of Copenhagen, said, “In this new collaboration we will have the opportunity to apply novel vaccine technologies developed at Mucosis and Expres2ion to our malaria vaccine antigen developed at University of Copenhagen, with the aim to develop such a vaccine that can offer women long term protection against malaria.”
Subscribe to our mailing list, and we'll keep you posted of the latest developments.